PM360 2023 Innovative Consumer Tech Medisafe Connected Health Platform

A screenshot of the Medisafe Connected Health Platform on a smartphone, which helps to seamlessly manage the medication journey

Medisafe Connected Health Platform

Improving Medication Adherence with Personalized Interventions

Medisafe was created to solve the problem of medication nonadherence and today uses AI and behavioral science to customize each patient’s experience, provide critical linkages to various healthcare services, and better support and engage with patients throughout their entire therapeutic journey. Through personalized digital health interventions, the Medisafe Connected Health Platform puts support in patients’ hands by providing a comprehensive solution that encompasses appointments, symptoms, measurements, reports, trials, care team connection, and personalized guidance, among other features.

For pharma companies, Medisafe’s Custom-Branded Solution and Software-as-a-Medical Device (SaMD) offering puts organizations in complete control of patients’ digital experiences, customized with a brand’s look and feel, all with the highest security to meet medical device regulatory standards. Medisafe’s SaMD technology can be launched by partners globally at any time and features a no-code, cloud-based platform that allows for easy scalability. Medisafe’s Software Development Kit (SDK) also helps pharma organizations extend their digital patient support by integrating individual modules including health/disease education, analytics, and more.

For example, in 2018 Merck KGaA partnered with Medisafe to pilot customized digital medication management programs across three emerging markets: Brazil, Russia, and Mexico. The companies designed programs that offered daily support and connectivity to patients’ specific medication dosing and condition needs; medication reminders that provided transparency into complex dosing schedules and could be shared with caregivers and HCPs; and condition-specific and/or lifestyle content targeted to patients at appropriate phases of their treatment journey.

The customized programs achieved an average adherence of 83% in only five months and 73% of patients said they were “Very or Extremely Satisfied” with the program.

Ads

You May Also Like

PM360 2019 Innovative Product ByTarget from CMI/Compas

ByTarget CMI/Compas Justin Freid, EVP, Growth & Innovation jfreid@cmicompas.com It’s the pharma marketer’s holy ...

PM360 2020 Innovative Strategy Beyond the Lockdown from IBM

Beyond the Lockdown IBM Partha Anbil, Business Area Leader, IBM Healthcare & Life Sciences ...

Healthcare Watch January/February 2023

Patient Pages: Insights into Adherence During Pregnancy Women’s health and pregnancy company Mirvie conducted ...